We have good medicines to treat conditions infections, heart disease, diabetes but when it comes to neurodegenerative diseases like Alzheimer’s or Parkinson’s, we still don’t have a cure that truly stops the disease.
There are real reasons for this, and understanding them shows both how challenging biology is and why progress takes time.
- The brain is extremely protected
The brain has a built-in shield called the blood–brain barrier (BBB).
This barrier: • Stops harmful substances in the blood from entering the brain
• Is very selective about what it lets through
So many drugs that work well elsewhere in the body can’t reach the brain at all, making it hard to treat brain diseases with conventional medicines.
- These diseases are not caused by a single problem
In infections, we target a clear enemy (bacteria/virus).
In high blood pressure, we target a biochemical pathway.
But in diseases like Alzheimer’s and Parkinson’s, multiple things go wrong simultaneously:
• Protein misfolding and plaque formation
• Neuronal death
• Inflammation
• Oxidative stress
• Genetic factors
So there isn’t one target to fix — it’s a network of ongoing damage.
- Brain cells don’t regenerate like other cells
If skin gets damaged, the body replaces it.
If blood cells are lost, bone marrow makes more.
But neurons (brain cells) do not regenerate easily once lost.
By the time symptoms appear, a lot of damage may already have happened.
So most current treatments aim to slow progression, not cure what’s already lost.
- Clinical trials for brain drugs are slow and complex
Testing medicines for brain diseases is tough because:
• Symptoms develop slowly over years
• Improvement is hard to measure objectively
• Side effects can be subtle or dramatic
• Cognitive effects are tricky to quantify
This makes trials long, expensive, and uncertain.
Examples of current drugs and limitations
Alzheimer’s disease: Donepezil, Rivastigmine, Galantamine
→ These improve symptoms temporarily but don’t stop disease progression.
Parkinson’s disease: Levodopa
→ Replaces dopamine but doesn’t protect neurons long-term.
Multiple Sclerosis (MS): Interferons, Fingolimod
→ Helps immune modulation, but still not a cure.
These drugs help manage symptoms or slow progression, but they don’t reverse or cure the underlying disease.
What can be improved
• Better drug delivery to the brain
→ Finding ways for medicine to cross the BBB safely.
• Earlier diagnosis
→ By the time symptoms show, damage is advanced.
• Targeting multiple disease pathways simultaneously
→ Because these diseases aren’t caused by a single factor.
Future directions in CNS drug research
Researchers are exploring:
Gene therapy — fixing genetic causes at the source
Neuroprotective agents — protecting neurons from dying
Immunotherapy — using the immune system to clear abnormal proteins
Nanotechnology & drug carriers — to help drugs cross the BBB
Biomarkers for earlier detection — catch disease before symptoms
Progress takes time, but the direction is exciting and promising.
Do you think future breakthroughs will come from biology, genetics, or better brain delivery systems?
MBH/AB